2016胰腺癌进展.pptVIP

评论 晚期胰腺癌研发中的新药 Slide 1 Presented By Eric Van Cutsem at 2016 ASCO Annual Meeting TH302：溴化异环磷酰氮芥 靶向缺氧的烷化剂 Slide 3 Presented By Eric Van Cutsem at 2016 ASCO Annual Meeting Randomized, double-blind phase III MAESTRO design Presented By Eric Van Cutsem at 2016 ASCO Annual Meeting Primary Endpoint: Overall survival ITT Presented By Eric Van Cutsem at 2016 ASCO Annual Meeting Progression-free survival Presented By Eric Van Cutsem at 2016 ASCO Annual Meeting RECIST 1.1 Response Rate Presented By Eric Van Cutsem at 2016 ASCO Annual Meeting Efficacy Summary: Asia (123 pts: 116 pts-Japan and 7 pts-South Korea) Presented By Eric Van Cutsem at 2016 ASCO Annual Meeting Conclusions Presented By Eric Van Cutsem at 2016 ASCO Annual Meeting 间质改良剂 hedgehog抑制剂：将间质全部消耗，失败告终 肿瘤基质的双重作用 新辅助化疗及辅助化疗进展； 晚期胰腺癌化疗的进展； 晚期胰腺癌的免疫治疗进展； ASCO2016进展汇报提纲 Treatment Schema MDT模式是否能边缘可切除胰腺癌R0切除率？ Treatment Overview Surgery and pathology 结论：MDT模式提高了边缘可切除胰腺癌R0切除率！ Slide 1 Presented By John Neoptolemos at 2016 ASCO Annual Meeting Slide 7 Presented By John Neoptolemos at 2016 ASCO Annual Meeting Tumour Pathology Presented By John Neoptolemos at 2016 ASCO Annual Meeting Slide 12 Presented By John Neoptolemos at 2016 ASCO Annual Meeting Treatment Received Presented By John Neoptolemos at 2016 ASCO Annual Meeting Reported Toxicity Presented By John Neoptolemos at 2016 ASCO Annual Meeting Slide 16 Presented By John Neoptolemos at 2016 ASCO Annual Meeting Survival by Treatment Presented By John Neoptolemos at 2016 ASCO Annual Meeting Slide 18 Presented By John Neoptolemos at 2016 ASCO Annual Meeting Slide 20 Presented By John Neoptolemos at 2016 ASCO Annual Meeting Conclusions Presented By John Neoptolemos at 2016 ASCO Annual Meeting 评论 JASPAC01：替吉奥辅助化疗优于吉西他滨 小结 新辅助化疗放疗对于边缘可切除胰腺癌有意义 吉西他滨联合希罗达有望成为胰腺癌辅助化疗新标准 对于亚洲人群：替吉奥单药也是好的选择 现在的标准： 标准的辅助化疗方案还是吉西他滨、5-Fu单药、替吉奥单药 辅助放疗对于淋巴结转移患者及切缘阳性患者有一定的应用价值。美国赞成术后辅助放疗，欧洲不赞成术后辅助放疗 新辅助与辅助化疗新进展； 晚期胰腺癌化疗的新进展； 晚期胰腺癌的免疫治疗新进展； ASCO2016进展汇报提纲 Folfirinox与mFolfirinox ASCO2016：对FOLFIRINOX方案